| Wang, Lin Wei |
NCT06285370: A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy |
|
|
| Recruiting | 4 | 20 | RoW | Mogamulizumab | Kyowa Kirin China Pharmaceutical Co., Ltd. | Cutaneous T-Cell Lymphoma | 10/25 | 01/26 | | |
NCT05950646: Mini-dose Dexmedetomidine-Esketamine Infusion and Perioperative Sleep Quality |
|
|
| Recruiting | 4 | 154 | RoW | Dexmedetomidine, Esketamine, Normal saline | Peking University First Hospital, Beijing Hospital | Old Age, Knee Replacement Surgery, Hip Replacement Surgery, Dexmedetomidine, Esketamine, Sleep Quality | 12/24 | 12/27 | | |
NCT05043870: Combined Immunosuppression for Pediatric Crohn's Disease |
|
|
| Recruiting | 4 | 128 | RoW | Infliximab and immunosuppressives, IFX, IMMs, AZA, MTX, Infliximab, IFX | Children's Hospital of Fudan University | Crohn Disease, Infliximab, Immunosuppression, Children, Only | 10/25 | 12/25 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis |
|
|
| Recruiting | 3 | 402 | RoW | Vedolizumab IV, Placebo | Takeda | Moderately to Severely Active Ulcerative Colitis | 05/28 | 07/28 | | |
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 133 | RoW | TJ107 +Pembrolizumab | TJ Biopharma Co., Ltd. | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 06/24 | 12/24 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT05690581: Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies |
|
|
| Recruiting | 1 | 146 | RoW | CM369 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumors and Hematologic Malignancies | 10/25 | 02/26 | | |
| Recruiting | N/A | 10254 | RoW | | Limeng Chen | Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder | 12/24 | 12/24 | | |
NCT06256315: Hyper-ERAS Program for Highly Selective Colorectal Cancer Patients |
|
|
| Recruiting | N/A | 160 | RoW | Hyper-ERAS Program | Peking University Cancer Hospital & Institute | Colorectal Cancer, ERAS | 06/25 | 08/25 | | |
NCT06256627: The Maintenance Treatment of "ITIVA" in AML Patients |
|
|
| Recruiting | N/A | 130 | RoW | recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine | Henan Cancer Hospital | Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease, Interferon-α-1b, Interleukin-2, Thalidomide, Venentoclax, Azacitidine | 03/25 | 05/27 | | |
NCT05246007: Nocturnal Low-dose Dexmedetomidine Infusion and Perioperative Sleep Quality |
|
|
| Not yet recruiting | N/A | 432 | RoW | Dexmedetomidine, Dexmedetomidine for infusion, Normal Saline, Normal Saline for infusion | Peking University First Hospital, Beijing Hospital | Old Age, Knee Replacement Surgery, Hip Replacement Surgery, Dexmedetomidine, Sleep Quality | 12/23 | 12/26 | | |
NCT06209099: Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer |
|
|
| Recruiting | N/A | 67 | RoW | Nonoperative Management (NOM), Local Excision (LE), Total Mesorectal Excision (TME) | Peking University Cancer Hospital & Institute | Rectal Cancer | 09/25 | 11/25 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program |
|
|
| Recruiting | N/A | 16000 | RoW | phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2 | Wuhan Union Hospital, China, Peking University First Hospital | Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease | 12/23 | 12/24 | | |
| Not yet recruiting | N/A | 1500 | RoW | adrenal venous sampling | Chinese Academy of Medical Sciences, Fuwai Hospital | Hyperaldosteronism | 12/26 | 12/26 | | |
EHCONSGDMC, NCT05911893: the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children |
|
|
| Not yet recruiting | N/A | 800 | RoW | high caloric oral nutritional supplements, high-energy total nutrition formula, nutritional education, dietary guidance | Children's Hospital of Chongqing Medical University, Anhui Provincial Children's Hospital, Baoji Maternity and Child Healthcare Hospital, Chengdu Women's and Children's Central Hospital, Guiyang Maternity and Child Health Care Hospital, Guangzhou Women and Children's Medical Center, Hunan Children's Hospital, Jiangxi Maternal and Child Health Hospital, Kunming Children's Hospital, Nanjing Maternity and Child Health Care Hospital, Children's Hospital of The Capital Institute of Pediatrics, Xianyang Children's Hospital, Nestle Health Science | Malnutrition, Child, Malnourishment, Nutritional Deficiency, Undernutrition | 02/25 | 06/25 | | |
TALENTop, NCT04649489: A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer with PVTT, HVTT or IVCTT After Initial Ate/Bev |
|
|
| Active, not recruiting | N/A | 501 | RoW | Atezolizumab, Bevacizumab, Surgery | Jia Fan | Venous Thrombosis | 08/27 | 03/28 | | |
NCT05670275: Microecology and Host Immunity in Patients With Severe COVID-19 Infection |
|
|
| Recruiting | N/A | 200 | RoW | | Chinese PLA General Hospital | Microbiome,Immune Function, Critically Ill | 06/23 | 06/23 | | |
| Song, Yongping |
NCT04971551: A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. |
|
|
| Not yet recruiting | 2 | 60 | RoW | Jaktinib Hydrochloride Tablets, Jaktinib | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Acute Graft-Versus-Host Disease | 06/25 | 07/25 | | |
FUMANBA-1, NCT05066646: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 132 | RoW | CT103A | Nanjing IASO Biotherapeutics Co.,Ltd | Multiple Myeloma | 10/22 | 06/24 | | |
NCT04230473: A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia |
|
|
| Completed | 1 | 10 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Relapsed or Refractory Acute Lymphoblastic Leukemia | 12/20 | 11/22 | | |
| Recruiting | 1 | 57 | RoW | TQB3473 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed/Refractory Hematological Malignancies | 12/21 | 06/22 | | |
NCT05576181: Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia |
|
|
| Not yet recruiting | 1 | 19 | NA | ThisCART19A, Fludarabine Oral Tablet, Cyclophosphamide, VP-16, etoposide, HSCT | Fundamenta Therapeutics, Ltd., The First Affiliated Hospital of Zhengzhou University | Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited | 01/25 | 07/25 | | |
| Wei, Xudong |
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. |
|
|
| Recruiting | 3 | 350 | RoW | Olverembatinib, Imatinib | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Ph+ ALL | 12/24 | 10/28 | | |
NCT04684147: Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 2 | 100 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Relapsed or Refractory Acute Lymphoblastic Leukemia | 09/22 | 12/26 | | |
NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
|
|
| Completed | 1/2 | 105 | RoW | TJ011133 | TJ Biopharma Co., Ltd. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) | 12/23 | 12/23 | | |
|
|
| Recruiting | 1/2 | 284 | RoW | APG-2575, Reduced-dose HHT, standard-dose HHT, Azacitidine | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy | 08/25 | 08/26 | | |
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia |
|
|
| Recruiting | 1/2 | 90 | RoW | BN104 | BioNova Pharmaceuticals (Shanghai) LTD. | ALL, Adult, AML, Adult | 06/26 | 06/27 | | |
NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies |
|
|
| Recruiting | 1 | 98 | RoW | HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study | Hutchmed | Hematological Malignancies | 10/27 | 12/27 | | |
NCT05641259: A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML |
|
|
| Recruiting | 1 | 198 | RoW | LP-108, Azacitidine | Guangzhou Lupeng Pharmaceutical Company LTD. | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 12/24 | 12/25 | | |
| Recruiting | 1 | 48 | RoW | TQB2928 Injection + Azacitidine for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 05/25 | 05/25 | | |
APG-115-AC101, NCT04275518: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. |
|
|
| Recruiting | 1 | 102 | RoW | APG-115, Azacitidine, Cytarabine | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | 12/25 | 12/25 | | |
NCT06256627: The Maintenance Treatment of "ITIVA" in AML Patients |
|
|
| Recruiting | N/A | 130 | RoW | recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine | Henan Cancer Hospital | Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease, Interferon-α-1b, Interleukin-2, Thalidomide, Venentoclax, Azacitidine | 03/25 | 05/27 | | |
NCT06472479: LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma |
|
|
| Not yet recruiting | N/A | 66 | RoW | LCAR-M61S cells preparation, Cyclophosphamide, Fludarabine, LCAR-M61D cells preparation | The First Affiliated Hospital with Nanjing Medical University, Nanjing Legend Biotech Co. | Relapsed/Refractory Multiple Myeloma | 08/28 | 10/29 | | |
